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Abstract
OBJECTIVES: To compare the safety and efficacy of iron carboxymaltose with ferrous sulfate to treat
iron deficiency anemia in the post partum. METHODS: Patients were randomized (2:1 ratio) to receive
iron carboxymaltose (up to 3 weekly doses of 1000 mg maximum, applied in 15 min; n=227) or ferrous
sulfate (100 mg twice daily, 12 weeks; n=117). Changes in hemoglobin and iron stores up to week 12
were analyzed. RESULTS: Iron carboxymaltose was as effective as oral iron sulfate in changing
hemoglobin, despite the much shorter treatment period (2 weeks vs 12 weeks). Ferritin levels were
significantly higher. Except for injection site burning, iron carboxymaltose was better tolerated than
ferrous sulfate, mainly concerning gastrointestinal side effects. There were no safety concerns identified
in breast-fed infants. CONCLUSION: Parenteral iron carboxymaltose is a safe and effective treatment
option for postpartum anemia, with advantages of a shorter treatment period, better compliance, rapid
normalization of iron storages, and lower incidence of gastrointestinal side effects.
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Synopsis 
Iron carboxymaltose is a safe and effective treatment in women with post-partum anemia. 
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This study compared efficacy and safety of iron carboxymaltose, a novel intravenous iron, with 
ferrous sulfate in treating iron deficiency anemia in women post-partum.  
Method 
Patients were randomized (2:1 ratio) to iron carboxymaltose (up to 3 weekly doses of maximum 
1000 mg applied in 15 minutes; n=227) or ferrous sulfate (100 mg bid, 12 weeks; n=117). 
Changes in hemoglobin and iron stores up to week 12 were analyzed.  
Result 
Iron carboxymaltose was as effective as oral iron sulfate in changing hemoglobin, despite the 
much shorter treatment period (2 weeks vs. 12 weeks). Ferritin levels were significantly higher. 
Except injection site burning, iron carboxymaltose was better tolerated than ferrous sulfate, 
mainly concerning gastrointestinal side effects. There were no safety concerns in breast-fed 
infants.  
Conclusion 
Parenteral iron carboxymaltose is a safe and effective treatment option for post-partum anemia, 
with advantages of a shorter treatment period, better compliance, rapid normalization of iron 
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Introduction 
Iron deficiency anemia (IDA) is very common in women post partum. Oral treatment with 
ferrous sulfate has been considered the standard of care in post-partum IDA, but parenteral iron 
treatment is expected to be advantageous in cases when oral iron therapy is not tolerated due to 
gastrointestinal adverse effects, in patients with poor compliance or in patients with more severe 
anemia, where intravenous iron treatment ensures a fast response to iron treatment. As a result, 
there is increased interest in parenteral iron therapy, which can provide a greater and more rapid 
iron supply than oral iron supplementation.[1,2,3,4,5,6]  
Recently, a new parenteral iron preparation, iron carboxymaltose, was developed to facilitate 
effective treatment of IDA as well as rapid replacement of iron stores. Iron carboxymaltose has a 
nearly neutral pH (5.0 to 7.0) and physiological osmolarity, which makes it possible to administer 
higher single doses over shorter time periods than other parenteral preparations.  
This study was carried out in women with post partum IDA, who were expected to benefit from 
the short treatment period permitted by the larger doses that can be given parenterally than orally. 
The aims of the study were to assess the effects of iron carboxymaltose on hemoglobin (Hb) 
increase, iron status, and safety for both mother and breast-fed infant.  
 
Material and Methods 
A multi-center, open-label, randomized, controlled, parallel group phase III study in women with 
post-partum IDA (Hb ≤105 g/L). Patients with anemia other than anemia caused by blood loss 
secondary to delivery and iron deficiency were ineligible. All patients provided written informed 
consent. Patients were randomized according to a 2:1 ratio (iron carboxymaltose:ferrous sulfate) 
with stratification by country and severity of anemia. Patients received either an intravenous 
infusion of iron carboxymaltose (FERINJECT®, Vifor International, St. Gallen, Switzerland) at a 
maximum dose of 1000 mg iron (15 mg iron/kg body weight if body weight <66 kg; over 
15 minutes) on Day 1, with subsequent doses at 1-week intervals until the patient’s calculated 
total iron requirement was reached (up to three weekly infusions), or oral ferrous sulfate 
(Plastufer, Valeant Pharmaceuticals International) 100 mg twice daily for 12 weeks. The patient’s 
total iron requirement was calculated using the modified formula of Ganzoni [7] and the iron 
carboxymaltose dose was adapted depending on body weight, ferritin and transferrin saturation 
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(TfS) levels. All patients received first study medication within 7 days post-partum and then 
attended follow-up visits after 1, 2, 4 and 12 weeks (end of study). Twenty centers in three 
countries included patients, with patient participation between June 2004 and August 2005. 
The primary objective of this study was to evaluate the efficacy of intravenous iron 
carboxymaltose vs. oral ferrous sulfate in treating IDA in women with post-partum anemia. 
Secondary objectives included investigation of the safety and tolerability of iron carboxymaltose 
vs. oral ferrous sulfate, and measurement of levels of iron in breastmilk from a subset of patients. 
Efficacy was assessed by change from baseline to week 12 in Hb levels (primary endpoint); 
changes from baseline in ferritin and TfS; the number and proportions of patients (‘response 
rate’) who achieved Hb levels of 120 to 160 g/L, ferritin levels of 50 to 800 µg/L, and TfS levels 
of 20 to 50%; the number and proportion of patients who needed transfusions. Measurement of 
iron-status parameters, as well as Hb, was performed by a central laboratory. Safety was assessed 
by means of treatment-emergent adverse events in the mother and breast-fed infant, vital signs, 
electrocardiogram, physical examinations and clinical laboratory panels. The study was approved 
by the relevant Independent Ethics Committees.  
The planned sample size of 348 patients was based on a 90% power to detect non-inferiority 
using a margin of 5 g/L (half the estimated clinically relevant change in Hb), an α of 0.025 
(1-sided), and expected standard deviation (SD) of 12 g/L, with a 20% dropout rate. The 
breastmilk substudy was performed at 2 sites in Romania, and the planned number of patients 
(10 in each group) was considered sufficient to gain insight into the effect of iron carboxymaltose 
on iron levels in breastmilk. Analyses of efficacy parameters were based on both the full 
analysis/intent-to-treat (ITT) set and the per-protocol (PP) set. For change in Hb from baseline to 
week 12, analysis was performed by calculating the two-sided 95% confidence interval (CI) for 
the difference “iron carboxymaltose minus ferrous sulfate” in Hb change, from an analysis of 
covariance (ANCOVA); non inferiority was concluded if the lower bound was ≥-5 g/L, and 
superiority if the lower bound was ≥0 g/L. Descriptive statistics (mean, SD, range) are presented 
for measured values and for absolute changes from baseline to all subsequent timepoints, 
including 95% CIs for changes from baseline. The same ANCOVA model as above was applied 
to continuous secondary efficacy endpoints to assess treatment differences. For response rates, 
number and proportion of patients were tabulated with the corresponding 95% CIs. A descriptive 
comparison of response rates between the two groups was performed by means of a 2-sided 
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chi-squared test, with a further exploratory analysis using the Cochran-Mantel Haenszel test with 
adjustment for severity of anemia, country and enrolment. Differences between groups in the 
number of patients experiencing adverse events by body system were tested using Fisher’s exact 
test. For all analyses, p-values <0.05 were considered statistically significant. Unless otherwise 




From 824 patients screened, 349 were randomized (Figure 1). Main demographic and baseline 
characteristics are summarized in Table 1; no differences between the groups were detected. The 
most common method of delivery in both groups was vaginal. Cesarean section was more 
common in Poland 6/11 [54.5%]) and Romania (976/145 [52.4%]) than in the Russian Federation 
(16/111 [14.4%]). Mean calculated iron deficit was similar between groups (1365.8 mg and 
1393.7 mg, respectively); the majority of patients in the iron carboxymaltose group required only 
1 or 2 infusions (mean total dose 1346.7 mg in the safety set). For breast-fed infants, no 
differences between groups for birth weight, head circumference, length or sex were detected.  
Mean compliance for ferrous sulfate capsules was >90% (by counts of returned unused capsules 
at the week 4 and 12 visits). Reasons for non-compliance included forgetting to take the tablets, 
taking 1 instead of 2 tablets, and losing or discarding the bottle. For iron carboxymaltose, 
compliance was 100%, with the exceptions of one patient with a compliance of 73% (the patient 




Hb levels increased from baseline to week 12 in both groups (Figure 2), increasing to a mean of 
130.4 g/L in the iron carboxymaltose group and 128.9 g/L in the ferrous sulfate (control) group 
(mean change from baseline 33.7 g/L and 32.9 g/L, respectively). There were no statistically 
significant differences between groups at any timepoint. Iron carboxymaltose was non-inferior to 
ferrous sulfate in terms of change in mean Hb from baseline to week 12. However, superiority 
could not be concluded because the lower limits of CIs were below zero at all time points 
analyzed (baseline to weeks 2, 4 and 12). An additional analysis evaluating only patients who had 
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baseline Hb ≤105 g/L supported the validity of the main analysis. There were no statistically 
significant differences between groups for response rate at any timepoint (Table 2).  
 
Ferritin 
In the iron carboxymaltose group, mean ferritin levels increased from 39.9 µg/L at baseline to 
568.2 µg/L at week 1 (Figure 3). A decrease was observed in the following weeks, but ferritin 
levels remained considerably above baseline at all visits (mean 161.2 µg/L at week 12). In 
contrast, patients in the control group showed only a marginal increase of ferritin levels 
(32.4 µg/L to 34.8 µg/L at week 2 and 43.3 µg/L at week 12). The change from baseline was 
significantly higher in the iron carboxymaltose group compared to the control group for all visits, 
including Week 12 (p<0.0001). Response rates for ferritin were also significantly higher in the 
iron carboxymaltose group than the control group at all timepoints (Table 2). 
 
Transferrin Saturation 
Mean values of TfS increased from baseline and remained >20% from week 2 to week 12 in both 
groups, reaching maximum mean values at week 4 (40.1% and 27.9%, respectively). Changes 
from baseline of mean TfS values were statistically significantly higher in the iron 
carboxymaltose group compared to the control group at all visits (p≤0.0004). Response rates for 
TfS were significantly higher in the iron carboxymaltose group at all visits (Table 2). 
 
Red Cell Indices 
No clinically relevant changes from baseline in mean corpuscular volume or mean corpuscular 
hemoglobin were detected (not analyzed statistically). There was an increase in mean reticulocyte 
counts in the iron carboxymaltose group only, from 71.0 x109/L at baseline to 110.6 x109/L at 
week 1, returning to 91.9 x109/L at week 2 and 60.9 x109/L at week 4. In the control group, mean 
reticulocyte counts showed no increase at any timepoint. 
 
Transfusions 
Only one patient (in the iron carboxymaltose group) had a transfusion to replace intraoperative 
blood loss (patient excluded from the PP set). 
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Tolerability in Mothers 
Iron carboxymaltose was well tolerated and treatment was not associated with any clinically 
relevant safety concerns. Overall, adverse events were experienced by 26.0% (59/227) of patients 
in the iron carboxymaltose group and by 22.2% (26/117) of patients in the control group 
(excluding adverse events relating to IDA or the therapeutic effect of iron treatment, eg, Hb 
decreased, ferritin increased) (Table 3). There was no statistically significant differences between 
the two groups in the overall adverse event profile (p=0.510). The body system with the highest 
incidence of events was ‘infections and infestations’ (nasopharyngitis and respiratory tract 
infection were the commonest events), with events in 8.4% and 3.4% of patients in the iron 
carboxymaltose and control groups, respectively, and no statistically significant differences 
between the groups (p=0.110). Statistically significant differences were seen in the following 
body systems (iron carboxymaltose vs. control): gastrointestinal disorders (3.5% vs. 10.3%; 
p=0.015), general disorders and administration site conditions (6.2% vs. 0%; p=0.003) and 
musculoskeletal and connective tissue disorders (0% vs. 2.6%; p=0.039). Constipation was less 
common in the iron carboxymaltose group (0.4% vs. 6.8%). Patients in the iron carboxymaltose 
group experienced infusion site burning (2.2%) and infusion site pain (1.3%). Only patients in the 
control group experienced arthralgia (1.7%).  
Adverse reactions (adverse events considered possibly, probably or certainly related to study 
drug) were experienced by 10.6% and 11.1% of patients in the iron carboxymaltose and control 
groups, respectively. Two patients in the iron carboxymaltose group and none in the control 
group experienced severe adverse reactions; hepatic enzymes increased and hypersensitivity. 
There were no cases of anaphylactic shock/reaction. Adverse reactions leading to discontinuation 
were infusion site burning and panic attack (1 patient), and rash (1 patient) in the iron 
carboxymaltose group, and diarrhea (1 patient) in the control group. Two patients, both in the 
iron carboxymaltose group (0.9%), experienced serious adverse events (endometritis in one 
patient and sepsis after vaginal hysterectomy in the other patient); none of these events were 
considered drug-related. 
There were no clinically relevant changes in vital signs or physical examinations during the 
study. Transient elevations in liver enzymes were observed in a minority of patients (see 
Table 3). Levels of ferritin and TfS indicating iron intoxication were not observed. 
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Breastmilk Substudy 
For 11 patients in the iron carboxymaltose group, mean iron in breastmilk increased from 
0.500 mg iron/kg breastmilk at baseline to a maximum of 1.447 mg/kg 24 hours post-dose. Mean 
values decreased to 0.513 mg/kg week 1 pre-dose, increased to 0.615 mg/kg 1-3 hours post-dose 
at week 1 and were 0.991 mg/kg at week 2, pre-dose. For 14 patients in the control group, mean 
iron values in breastmilk decreased from 0.407 mg/kg at baseline to 0.332 mg/kg 48 hours 
post-dose. Mean values increased slightly over time up to 0.779 mg/kg at week 2, pre-dose. Mean 
iron breastmilk values were significantly higher in the iron carboxymaltose group at 48 hours 
after the first dose (+0.101 mg/kg versus -0.075 mg/kg, respectively; p=0.0052).  
 
Tolerability in Breast-fed Infants 
Adverse events in breast-fed infants are summarized in Table 3. The low frequency of adverse 
events in both groups was too small to draw any meaningful conclusion. However, there was no 
evidence of adverse effects of iron carboxymaltose on breast-fed infants. 
 
Discussion 
In this study, parenteral and oral iron treatment were both effective in treating post-partum IDA 
over 12 weeks. Based on the primary efficacy variable (Hb increase at week 12), iron 
carboxymaltose was non-inferior to ferrous sulfate, and the similarity of results in the PP and ITT 
sets supports the robustness of the results. Thus, parenteral iron carboxymaltose is as effective as 
oral ferrous sulfate in treating post-partum IDA despite the much shorter treatment period, and a 
lower total dose of iron (mean 1346.7 mg versus 16.8 g), highlighting the efficient utilization of 
parenteral iron.  
In the iron carboxymaltose group, increases in ferritin and TfS were significantly greater than in 
the ferrous sulfate group at all timepoints, demonstrating a successful increase in iron storage and 
availability for erythropoiesis. The decrease in ferritin after week 2 in the iron carboxymaltose 
group indicates utilization of stored iron during the weeks of increased hematopoiesis, as 
supported by the increase in reticulocyte counts. This increase in iron stores is a significant 
benefit over oral iron, which does not replenish iron stores in patients with IDA. Further, these 
results indicate that iron carboxymaltose may be advantageous in patients with severe anemia, 
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including those receiving rHuEpo treatment, where rapid availability of iron is 
important.[3,8,9,10,11,12,13,14] 
In the substudy of iron in breastmilk, mean iron values increased from baseline to week 2, 
pre-dose, in both groups. The iron breastmilk values were significantly higher in the iron 
carboxymaltose group at 48 hours after the first dose. However, the small number of patients 
included in the substudy and the high degree of inter-individual variation makes treatment group 
comparisons inconclusive.  
Iron carboxymaltose was well tolerated by patients with post-partum IDA at 1 to 3 single doses. 
The overall adverse event profile was similar between groups, and there were no treatment-
related serious adverse events. The significantly higher frequency of gastrointestinal disorders in 
the ferrous sulfate group supports the findings of other studies, that oral iron medications are 
known to cause gastrointestinal side effects.[15,16] Even in this study, where compliance to oral 
therapy was encouraged and monitored (unlike the ‘real-life’ situation), and was very high 
(>90%), iron stores were not replenished. This is of particular concern in patients with more 
severe IDA, as they are at higher risk of recurrent IDA once menstruation restarts, and the iron 
deficit could be carried forward into subsequent pregnancies. Iron carboxymaltose also has 
several advantages over other parenteral iron preparations. It does not contain dextran and does 
not react with dextran antibodies, and thus there is no risk of anaphylactic reactions of the type 
seen with iron dextran.[17] In addition, iron carboxymaltose has positive characteristics 
compared to iron sucrose (Venofer®), which include a lower pH, lower osmolarity, and higher 
single dose administration.[18] Due to its safety profile, it can be given over a short-term period 
in in-patient or out-patient facilities. 
In conclusion, iron carboxymaltose is a safe and effective treatment option for patients with 
post-partum IDA, and no evidence of risk to their breast-fed infants. Iron carboxymaltose has 
advantages over oral ferrous sulfate of a shorter treatment period, ensured compliance, no 
gastrointestinal side effects, and replacement of iron stores. Thus, iron carboxymaltose should be 
ideally suited for treatment of patients with IDA who cannot tolerate oral iron supplementation, 
or in patients requiring rapid replenishment of iron stores.  
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Table 1 Demographic and Baseline Characteristics: Safety (N=344), PP Sets (N=268) 









Age (years)     
Mean (SD) 27.7 (5.5) 27.8 (5.4) 27.5 (5.4) 27.4 (5.1) 
Range 18 - 44 18 - 44 19 – 41 19 - 40 
Body Mass Index (kg/m2)     
Mean (SD) 22.70 (4.24) 22.78 (4.31) 22.35 (3.33) 22.55 (3.31) 
Range 16.3 - 42.7 16.3 - 42.7 14.7 - 32.9 14.7 - 32.0 
Delivery Method, N (%)     
Vaginal 145 (64.2) 113 (63.5) 71 (60.7) 54 (60.7) 
Cesarean section 80 (35.4) 65 (36.5) 42 (35.9) 33 (37.1) 
Forceps - - 4 (3.4) 2 (2.2) 
Vacuum 1 (0.4) - - - 
Hemoglobin (g/L) *     
Mean (SD) 96.6 (14.6) 96.7 (14.7) 97.6 (15.8) 96.0 (12.8) 
Range 52 - 145 52 - 145 62 – 173 66 - 129 
Ferritin (µg/L) *     
Mean (SD) 45.5 (110.9) 39.9 (63.7) 33.4 (27.7) 32.4 (21.7) 
Range 2 - 1392 2 - 605 0 – 218 0 - 117 
Transferrin Saturation (%) *     
Mean (SD) 12.1 (9.9) 11.7 (8.8) 12.8 (9.5) 12.2 (9.0) 
Range 2 - 74 2 - 54 2 – 51 2 - 46 
Calculated Iron Deficit (mg)     
Mean (SD) 1363.1 (181.9) 1365.8 (179.7) 1383.5 (186.0) 1393.7 (175.2) 
Range 720 - 2024 720 - 2024 829 – 2062 829 - 1918 
* Last measurement prior to first study drug administration.  
Not analyzed statistically for treatment group differences. 
Abbreviations: SD: standard deviation.  
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Table 2:  Response Rates for Hemoglobin, Ferritin and Transferrin Saturation: PP Set 
(N=268) 
Efficacy Parameter (Target Values) Response Rate  
 Iron carboxymaltose Ferrous sulfate p-values * 
 N (%) 95% CI N (%) 95% CI  
Hemoglobin (120-160 g/L)      
Week 2  95 (53.1) 45.8 - 60.2 42 (47.2) 37.2 - 57.5 NS 
Week 4 140 (78.2) 71.6 - 83.6 63 (70.8) 60.6 - 79.2 NS 
Week 12 152 (84.9) 78.9 - 89.4 73 (82.0) 72.8 - 88.6 NS 
Ferritin (50-800 µg/L)      
Week 2  127 (70.9) 63.9 - 77.1 12 (13.5) 7.9 - 22.1 <0.0001 
Week 4 150 (83.8) 77.7 - 88.5 15 (16.9) 10.5 - 26.00 <0.0001 
Week 12 139 (77.7) 71.0 - 83.1 29 (32.6) 23.7 - 42.9 <0.0001 
Transferrin saturation (20-50%)      
Week 2  125 (69.8) 62.7 - 76.1 32 (36.0) 26.8 - 46.3 <0.0001 
Week 4 130 (72.6) 65.7 - 78.6 45 (50.6) 40.4 - 60.7 ≤0.0002 
Week 12 139 (77.7) 71.0 - 83.1 59 (66.3) 56.0 - 75.3 <0.05 
* Statistical tests: Chi-squared test or Cochran-Mantel-Haenszel test with stratification adjustment for severity of 
anemia, country and enrolment. 
Abbreviations: CI: confidence interval, NS: non significant. 
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Table 3:  Tolerability of Iron Carboxymaltose and Ferrous Sulfate in Mothers (N=344) 
and in Breastfed Infants (N=346) 
Adverse events in mothers * Iron carboxymaltose 
(N=227) 
n (%) 
Ferrous Sulfate  
(N=117) 
n (%) 
At least one adverse event 59 (26.0) 26 (22.2) 
Nasopharyngitis 7 (3.1) 2 (1.7) 
Constipation 1 (0.4) 8 (6.8) 
Headache 6 (2.6) 2 (1.7) 
Alanine aminotransferase increased 5 (2.2) 3 (2.6) 
Infusion site burning 5 (2.2) 0 (0.0) 
C-reactive protein increased 4 (1.8) 0 (0.0) 
Uterine hemorrhage 3 (1.3) 1 (0.9) 
Changes in liver function tests ** 8 (3.5) 3 (2.6) 
Adverse events in breast-fed infants * (N=229) (N=117) 
At least one adverse event 24 (10.5) 14 (12.0) 
Constipation 3 (1.3) 4 (3.4) 
Erythema 5 (2.2) 0 (0.0) 
Diarrhea 3 (1.3) 0 (0.0) 
Nasopharyngitis 2 (0.9) 1 (0.9) 
Abdominal pain 1 (0.4) 2 (1.7) 
Upper respiratory tract infection 1 (0.4) 2 (1.7) 
* Event terms reported in 4 or more mothers or in 3 or more breast-fed infants in total, in descending order of 
frequency. 
** Reported as: elevated aspartate aminotransferase, and/or alanine aminotransferase, bilirubin or 
gamma-glutamyl transpeptidase 
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Excluded (n= 475) 
(Mostly patients with insufficient 
anemia) 
Analyzed safety & ITT (n= 227) 
Analyzed PP (n= 179) 
Excluded from PP analysis (n= 48) 
 - Major protocol deviation (n= 19) 
 - Premature discontinuation (n= 29) 
Analyzed safety & ITT (n= 117) 
Analyzed PP (n= 89) 
Excluded from PP analysis (n= 28) 
- Major protocol deviation (n= 13) 




Safety set (n= 344) 
ITT set (n= 344) 
PP set (n= 268) 
Follow-Up 
Assessed for eligibility 
(n= 824) 
Discontinued prematurely:  
(n= 29) 
  - Adverse event (n= 3) 
  - Consent withdrawal (n= 13) 
  - Lost to follow-up (n= 7) 
  - Non-compliance (n= 6) 
Iron Carboxymaltose 
 
Received treatment (at least one dose) 
(n= 227) 
Did not receive allocated treatment or 
had no efficacy data available 
(n= 4) 
Discontinued prematurely:  
(n= 15) 
  - Adverse event (n= 1) 
  - Consent withdrawal (n= 7) 
  - Lost to follow-up (n= 3) 
  - Non-compliance (n= 4) 
Ferrous Sulfate 
 
Received treatment (at least one dose) 
(n= 117) 
Did not receive allocated treatment or 
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Figure Titles and Legends 
 
Figure 1:  Disposition of Patients. 
Abbreviations: PP: Per-protocol, ITT: Intent-to-treat. 
 
Figure 2:  Mean ± Standard Deviation Hemoglobin Levels (g/L) by Visit – Per Protocol 
Population (N=268). 
 
Figure 3: Mean ± Standard Deviation Ferritin Levels (µg/L) by Visit – Per Protocol Population 
(N=268) 
 
